key: cord-0019789-un1wozy8
authors: Unterman, Irene; Bloch, Idit; Cazacu, Simona; Kazimirsky, Gila; Ben-Zeev, Bruria; Berman, Benjamin P; Brodie, Chaya; Tabach, Yuval
title: Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome
date: 2021-08-06
journal: nan
DOI: 10.7554/elife.67085
sha: 46c5ba569133e2b66defa7949d28289b36058457
doc_id: 19789
cord_uid: un1wozy8

Inactivating mutations in the Methyl-CpG Binding Protein 2 (MECP2) gene are the main cause of Rett syndrome (RTT). Despite extensive research into MECP2 function, no treatments for RTT are currently available. Here, we used an evolutionary genomics approach to construct an unbiased MECP2 gene network, using 1028 eukaryotic genomes to prioritize proteins with strong co-evolutionary signatures with MECP2. Focusing on proteins targeted by FDA-approved drugs led to three promising targets, two of which were previously linked to MECP2 function (IRAK, KEAP1) and one that was not (EPOR). The drugs targeting these three proteins (Pacritinib, DMF, and EPO) were able to rescue different phenotypes of MECP2 inactivation in cultured human neural cell types, and appeared to converge on Nuclear Factor Kappa B (NF-κB) signaling in inflammation. This study highlights the potential of comparative genomics to accelerate drug discovery, and yields potential new avenues for the treatment of RTT.

Rett syndrome (RTT [MIM: #312750]) is a rare genetic disorder caused by mutations in the methyl-CpG binding protein 2 (MECP2) gene (Amir et al., 1999) . It is an X-linked dominant disorder, almost exclusively affecting females. RTT is characterized by normal early development followed by regression, loss of purposeful hand movements, and intellectual disability (Liyanage and Rastegar, 2014) . Characteristics of the disease such as age of onset, range of symptoms, and their severity vary between patients (Neul et al., 2008) . The MECP2 protein has a role in transcriptional regulation but its exact mechanism of action, co-factors and downstream targets, are not fully characterized (Picard and Fagiolini, 2019) .

The MECP2 protein, as a transcriptional regulator, has been linked to both gene silencing and activation (Horvath and Monteggia, 2018) . It binds methylated CG dinucleotides through its methyl-binding domain and has a transcriptional repression domain that mediates binding to corepressor proteins . These two domains are hotspots for missense, nonsense, and frameshift mutations for RTT disease (Ragione et al., 2016; Krishnaraj et al., 2017) . Transcriptomic analyses of RTT patient postmortem brain tissues, blood samples, cell lines, and murine models (Shovlin and Tropea, 2018) have revealed hundreds of affected genes but with a low degree of overlap between studies (Picard and Fagiolini, 2019) .

Therapies aiming to restore MECP2 loss of function are in early development stages and are not approved for patients. These include attempts at read-through inducing drugs to overcome nonsense mutations (Brendel et al., 2011; Merritt et al., 2020) , X reactivating therapies to allow expression of silenced endogenous MECP2 (12), and gene therapy treatments to introduce wildtype MECP2 copies into the brain (Guy et al., 2007; Garg et al., 2013) . Furthermore, current gene therapy methods show limited transduction efficiency and are unable to modify all cells in the target tissue (Gadalla et al., 2013) . Targeting factors downstream of MECP2 offers a promising avenue which could allow for partial amelioration of Rett symptoms, without the severe neurological phenotypes associates with MECP2 overexpression (Chao and Zoghbi, 2012; Ramocki et al., 2009) .

One major downstream target of MECP2 is brain-derived neurotrophic factor (BDNF) (Chen et al., 2003) , a key modulator of neuronal development and function. BDNF levels are reduced in symptomatic MECP2 KO mice (Kline et al., 2010) and experimental interventions that increase BDNF levels improve RTT-like phenotypes (Chang et al., 2006) . The IGF-1 protein potentiates BDNF activity, and treatments with recombinant human IGF-1 and its analogs have led to improvement in several clinical measurements (Khwaja et al., 2014; Glaze et al., 2019) , with a trial of an IGF-1 synthetic analog currently in Phase 3 (NCT04181723). Additional trials include the administration of triheptanoin supplementation which is being investigated in a Phase two clinical trial (NCT02696044) to target mitochondrial dysfunction in RTT (Park et al., 2014) . Other interventions, such as ketamine (NCT03633058), targeting N-methyl-D-aspartate receptor (NMDAR) dysfunction, and Anavex 2-73 (NCT03758924), aimed at restoring mitochondrial dysfunction , are currently being studied. Histone deacetylases (HDACs) mediate MECP2 gene repression, and have also been suggested as therapeutic targets for Rett syndrome (Shukla and Tekwani, 2020) , which may act on BDNF trafficking (Xu et al., 2014) . The lack of a successful therapy to date emphasizes the need for accurate and comprehensive mapping of the MECP2 network with a focus on targetable proteins that could be used for interventions (Vashi and Justice, 2019) . Here, we use a genomics approach that has thus far not been applied to MECP2 (phylogenetic profiling), combined with data from drug target databases, to construct such a map.

A well-tested approach for gene functional prediction and identification of functional gene networks is phylogenetic profiling (PP), which analyzes gene conservation patterns across an evolutionary related set of organisms (Pellegrini et al., 1999) . Genes with similar evolutionary patterns are functionally coupled, irrespective of sequence homology (Date and Marcotte, 2003) . PP was used successfully to predict protein function (Enault et al., 2004; Eisen and Wu, 2002; Jiang, 2008; Merchant et al., 2007) , protein interactions (Kim and Subramaniam, 2006; Sun et al., 2005) and protein localization within the cell (Marcotte et al., 2000; Pagliarini et al., 2008; Avidor-Reiss et al., 2004; Hodges et al., 2012) . When a pathway becomes non-functional in a specific lineage (often due to loss of a key gene in the pathway), then other genes involved in the pathway may lose the fitness advantage they provide to the organism if they are not involved in other important pathways/functions. PP captures these pathway-level loss events, providing a quantitative measurement of functional relatedness and prioritizing those genes minimally involved in the same pathway over pleiotropic genes required in multiple pathways. This property is especially attractive for drug development, where the goal to is target the most specific proteins possible. Because PP is based on evolutionary dynamics rather than protein expression or sequence/structure features, it produces results that are highly complementary to traditional methods (Dey et al., 2015; Arkadir et al., 2019) .

In our recent work, we developed an improved version of PP that normalizes signals across hundreds of eukaryotic genomes to identify important new members of cellular and disease pathways (Arkadir et al., 2019; Sherill-Rofe et al., 2019; Tabach et al., 2013a; Tabach et al., 2013b; Schwartz et al., 2013) . As protein function and evolution are very complex (Bloch et al., 2020) , coevolution within a local lineage (i.e. mammals, vertebrates, fungi, etc.) can provide complementary evidence, and is especially informative for genes with multiple functions that show complex or recent evolution (Sherill-Rofe et al., 2019) . We recently incorporated a clade-specific analysis into our Normalized Phylogenetic Profile (NPP) software pipeline (Tsaban et al., 2021) , which is used for all the analyses in this study. We have used several functional databases including CORUM (Ruepp et al., 2008) , KEGG (Kanehisa and Goto, 2000) , and REACTOME (Jassal et al., 2020) to validate the NPP method and show that it recovers known protein complexes and pathways with higher specificity and sensitivity than other phylogenetic methods (Bloch et al., 2020; Tsaban et al., 2021) .

We combined our PP-derived interaction map of MECP2 with drug targeting databases to select new candidate drugs for RTT. There are thousands of known bioactive compounds collected in databases such as Drug-Gene interaction database (DGIdb) (Cotto et al., 2018) and Open Targets (Oxford Academic, 2019) , that contain information about validated direct or indirect effect on specific proteins or pathways. Network-based drug discovery methods are emerging as important tools to identify novel drug targets and predict the drug's mode of action and potential side-effects (Iorio et al., 2013) , and have been associated with higher success rates in clinical trials (Nelson et al., 2015; Pushpakom et al., 2019) . From our PP network, we selected three proteins that showed robust co-evolution with MECP2 across multiple evolutionary scales, had related roles in inflammation, and could be targeted by pharmacologically-validated compounds. These three compounds -pacritinib, EPO and DMF -were then functionally validated in MECP2 Knock-Down (KD) human neural cells, including microglia, astrocytes and neural stem cells. The ability of all these drugs to reverse some aspects of the MECP2-KD phenotypes demonstrates how comparative genome analysis can be used to understand and target this disease network.

Phylogenetic profile analysis of MECP2 in eukaryotes and mammals identifies MECP2 co-evolved genes To trace the evolutionary history of MECP2, we used BLASTP (Camacho et al., 2009) to compare the MECP2 protein to the proteomes of 1028 eukaryotic species. We repeated the process for each of 20,192 human transcripts to generate a profile of conservation for each human gene. The scores were normalized according to sequence length and the evolutionary distance between humans and the queried species as described previously (Tabach et al., 2013b; Bloch et al., 2020) . This Normalized Phylogenetic Profile (NPP) describes how conserved a transcript is in each species across the tree of life, compared to its expected conservation. Genes with similar NPPs (i.e. genes that are either conserved or lost as a group) are functionally related, often belonging to the same pathway (Sherill-Rofe et al., 2019; Tabach et al., 2013a; Tabach et al., 2013b; Schwartz et al., 2013) . We have shown that both across-clade and within-clade measures of co-evolution can be informative, and thus we computed NPPs both across all eukaryotes ( Figure 1A and Bloch et al., 2020; Tsaban et al., 2021; Braun et al., 2020) .

We first used NPP scores to sort all human genes by their phylogenetic similarity to MECP2 across eukaryotes ( Figure 1A and (Unterman et al., 2021 ; copy archived at swh:1:rev:14063b44a40688a8024a06347b63cfdac74b96ad)]. These two lists find correlated evolution at different scales, billions of years for eukaryotes and hundreds of millions for mammals. Therefore, the M200 set may show genes more recently co-evolved with MECP2. E200 and M200 had very different functional properties, based on STRING enrichment to Gene Ontology and other annotation sets (Supplementary file 2) The E200 list was enriched in a number of different functional categories, with some of the most significant related to innate immunity and the immune response. These included MHC Class II receptor activity and peptidoglycan receptor activity in GO, and the associated autoimmunity Asthma, Allograft rejection, and Type I in KEGG. In contrast, the M200 list had almost no functional enrichment, except for the general 'Disease' category within Uniprot annotated keywords.

The E200 and M200 lists had 10 genes in common ( Figure 1C ). As mammals are included within the eukaryote analysis, the two lists are not independent and thus the expected degree of overlap is hard to determine. Nevertheless, in two independent gene lists of this size we would only expect two overlapping genes. We thus considered the set of 10 overlapping genes, as well as the full union set of 390 genes, as two tiers of candidates for further exploration. A GeneAnalytics query of the 390 gene union set revealed it was enriched with genes expressed in the brain (p-value < 0.00024), with 79 genes linked to the cerebral cortex and 54 to the cerebellum ( the complementary role phylogenetic analysis to other measurements and predictions of protein interaction.

We chose to focus on the subset of MECP2 co-evolved genes that could be targeted by readily available compounds. This approach allows for straightforward functional testing in both in vitro and animal models of MECP2 inactivation and moves us closer to the ultimate goal of identifying a candidate therapeutic for RTT. Using DGIdb (Cotto et al., 2018) and Open Targets (Oxford Academic, 2019), we searched specific drug-gene interaction types (e.g. inhibitory, activating) to identify direct effects on the 390 candidate genes. Open Targets identified such protein-compound interactions for 11 proteins from our list, and DGIdb identified an additional 22, resulting in 33 druggable proteins in the MECP2 phylogenetic network. MECP2-linked proteins were neither more or less druggable than other proteins in the genome, since the number expected by chance was 39.9±6.0. Two of the 33 druggable NPP-linked proteins (IRAK1 and EPOR) were found in both the eukaryotic E200 and the mammalian M200 lists, and were targeted by compounds with clinical efficacy and acceptable safety profiles (Pacritinib and EPI), making these immediately attractive for further study. In a STRING (Szklarczyk et al., 2019) functional interaction map, which is based on independent data types, IRAK1 was one of the six proteins functionally linked to MECP2, whereas EPOR had no known functional links ( Figure 2A ). To identify additional targets among the 31 druggable NPPlinked proteins found in only one of the E200 and M200 lists, we investigated chromosomal clusters of genes with MECP2-linked genes, since clustered genes often indicate a shared evolutionary function. Indeed, IRAK1 is directly adjacent to MECP2 on an evolutionary conserved chromosomal band on the X chromosome ( Figure 2B and Figure 2-figure supplement 1). In a chromosomal clustering analysis of all MECP2-linked genes, the chr19p13.2 band contained more MECP2 co-evolved genes than any other in the genome ( Figure 2C ). Unexpectedly, this 5.6 Mb domain contained 5 of the 33 druggable MECP2 coevolved genes -EPOR, DNMT1, ICAM1, ICAM3, and KEAP1 ( Figure 2D ), making this the most strongly enriched band in the genome (p<1E-5, Figure 2D and Figure 2-figure supplement 2). Topologically Associated Domains (TADs) define the 3D organization of functionally co-regulated gene clusters (Fritz et al., 2019) , and the entire chr19p13.2 gene cluster defines a single TAD-based high-resolution Hi-C mapping (Rao et al., 2014;  Figure 2E ). Additionally, this region has been shown to be bound by MECP2 (Yasui et al., 2007) .

For the two druggable proteins found in both NPP lists (IRAK1, EPO1) and the other four proteins located in the chr19p13.2 TAD (DNMT1, ICAM1, ICAM3, KEAP1), we further investigated the associated drug's mode of action and efficacy and safety profile in other contexts. IRAK1 has been identified as a key intermediary in NF-kB signaling in RTT, with MECP2 directly binding the IRAK1 promoter to regulate its expression in MECP2-null mouse brains and NFKB1 dramatically increasing lifespan in MECP2 null mice (Kishi et al., 2016) . Pacritinib is a JAK2/FLT3 inhibitor with IRAK1 inhibiting capabilities (Jensen et al., 2017) , presently under clinical investigation for myelofibrosis and glioblastoma. As it is currently the only clinical stage IRAK1 inhibitor with known clinical efficacy and acceptable safety even after prolonged administration (Singer et al., 2018) , we chose this compound for our functional studies to target IRAK1.

EPOR forms a heterodimer with b common receptor (bCR), also known as the Tissue-Protective Receptor (TPR) (Brines et al., 2004) . The endogenous hormone EPO binds the TPR activating signaling cascades with roles in neuroprotection (Rey et al., 2019) . EPO has a very well understood pharmacological profile, and several variants of erythropoietin lacking hematopoietic effects have been developed and shown to preserve the neuroprotective effects of EPO administration (Chen et al., 2015; Patel et al., 2011) .

KEAP1 is the key repressor of the transcription factor nuclear factor erythroid 2-related factor 2 (NFE2L2), which is involved in response to antioxidants through its transcriptional regulation of inflammatory pathways. Dimethyl fumarate (DMF) is an approved treatment for both multiple sclerosis and psoriasis (Torkildsen et al., 2016; Blair, 2018) . Its administration decreases KEAP1 levels, increases NFE2L2 levels and causes dissociation and nuclear transport of NFE2L2. DMF treatment has proven to be effective and safe in conferring neuroprotection (Montes Diaz et al., 2018) .

Since the three candidate proteins targeted by these drug products (IRAK1, EPOR, and KEAP1) all have possible roles mediating inflammation, we chose to proceed with these for functional studies in cells modeling neural inflammatory phenotypes. The other three proteins identified (DNMT1, ICAM1, and ICAM3) may also be interesting targets for future study.

To analyze the effects of the three selected compounds on a RTT model system, we employed human immortalized primary neural cells silenced for MECP2. We chose to use a human in vitro model system for preliminary validation due to the significant differences in the phenotypes and functions of mouse and human neural cells . Indeed, recent studies reported the use of iPSCs and immortalized glial cells as reliable human models for analyzing specific therapeutic targets for various diseases including autism (Tsilioni et al., 2020) , neuroinflammation (Chiavari et al., 2019; Timmerman et al., 2018) and for analyzing the crosstalk of glioma with glial cells (Henrik Heiland et al., 2019; Zeng et al., 2020; Bier et al., 2020) . Since all three selected compounds were associated with changes in neuroinflammation, we first focused on microglia and astrocytes. Loss or impaired function of MECP2 has been reported to affect the functions of glial cells and these changes have been implicated in the pathogenesis of RTT (Kahanovitch et al., 2019; Jin et al., 2017) . We first characterized the effects of MECP2 silencing on the phenotypes of microglia (Figure 3) . For these experiments, we transduced the cells with lentivirus vectors expressing control or MECP2 shRNAs. The expression of MECP2 was silenced by over 80% in these cells (Figure 3-figure supplement 1) . MECP2 silencing induced a relative increase in the expression of M1 markers (IL1, and CD86) and a relative decrease of M2 markers (CD206 and IL-13) ( Figure 3A) , suggesting an increase in neuroinflammation. We also found that MECP2 silencing decreased the phagocytosis of the microglia cells ( Figure 3B) .

We next analyzed the effect of MECP2 silencing on human astrocyte differentiation and functions. For these experiments, neural stem cells (NSCs) were transduced with lentivirus vectors expressing the differentiation reporters, GFP/fLuc GFAP or the mCherry/Luc MAP2. The cells were plated on laminin coated plates and luciferase activity was determined 10 days later. In accordance with previous reports (Andoh-Noda et al., 2015; Mok et al., 2020) , we found that MECP2 silenced NSCs displayed preferential expression of the glial differentiation marker (GFAP) with a concomitant decrease in expression of the neuronal differentiation marker (MAP2) ( Figure 3C ). The MECP2 silenced astrocytes expressed lower levels of Excitatory Amino Acid Transporter 2 (EAAT2), indicating impaired function of these cells, as was suggested for mouse astrocytes (Okabe et al., 2012 ; Figure 3D ).

We finally examined the effects of MECP2 silencing on the expression of BDNF in human neurons and astrocytes and found that, as reported for mouse cells (Chang et al., 2006; Li et al., 2012) , MECP2 silencing decreased the expression of BDNF mRNA in both astrocyte and neuronal cultures ( Figure 3E) . Altogether, these finding indicate that the immortalized human cells employed in this study represent a reliable model for studying MECP2-related pathways and potential treatments.

We then analyzed the effects of the three selected compounds, DMF, EPO and pacritinib, on MECP2 silenced cells. We first demonstrated that in the concentrations range we used, none of these compounds exerted a toxic effect on neither microglia cells, astrocytes, primary neuronal cells nor NSCs (Figure 3-figure supplement 2) .

Control and MECP2 silenced microglia were treated with the DMF, EPO, and pacritinib, and their effects on the relative expression M1 (IL1, TNFa and CD86) and M2 (CD206 and IL-13) markers were determined using RT-PCR. While MECP2 wild-type cells were unchanged by the three compounds, all three abrogated the M1 shift induced by MECP2 silencing, albeit to a different degree ( Figure 4A-C) . EPO exerted the most significant effect, abrogating the effects of MECP2 silencing in all five marker genes ( Figure 4A ). In contrast, both DMF and pacritinib exerted only partial effects, abrogating the effects of MECP2 silencing in CD206, CD86, and IL-1, but failing to abrogate the effects on IL-13 and TNF-a ( Figure 4B-C) . We also analyzed the effects on phagocytosis in microglia cells. Treatment of MECP2 silenced cells with DMF exerted a significant increase in the phagocytosis of the silenced cells, whereas EPO and pacritinib did not ( Figure 4D ).

Knockdown of MECP2 has been reported to lead to increased NF-kB activity in neuronal and myeloid cells (O'Driscoll et al., 2015) and this deregulated activity has been associated with neuroinflammation and decreased dendritic arborization and spine density in a mouse model of RTT (Kishi et al., 2016) . We therefore examined the ability of our three candidate compounds to abrogate the increased NF-kB activity in MECP2 KD microglia cells. MECP2-silenced microglia cells were transfected with lentivirus vectors expressing the NF-kB luciferase reporter and a constitutively active Renilla luciferase construct (as a transfection control). The cells were treated with EPO, DMF , and neurons (E) were silenced for MECP2 using lentivirus vector. The relative expression of M1 and M2 markers was analyzed in microglia cells using RT-PCR (A) and degree of phagocytosis using the pHrodo assay (B). NSCs were transduced with lentivirus vectors expressing the differentiation reporters GFAP and MAP2 and were differentiated as described in the methods. Ten days later, luciferase activity was determined (C). Astrocytes silenced for MECP2 were analyzed for the expression of EAAT2 using western blot analysis (D) and the expression of BDNF mRNA in both MECP2 silenced astrocytes and neurons was determined using RT-PCR (E). The results are a representative experiment of three separate tests analyzed in quadruplet. **p<0.01, ***p<0.001, ****p<0.0001. The online version of this article includes the following figure supplement(s) for figure 3: and pacritinib for 24 hr and luciferase activity was determined thereafter. A significant increase in NF-kB-dependent luciferase activation was observed for EPO and DMF in the MECP2-silenced cells ( Figure 4E ), indicating that EPO and DMF were able to downregulate the increased NF-kB activation in MECP2 KD cells.

Various studies support a non-cell-autonomous effect of astrocytes on neuronal cell functions and contribution of astrocytes to various aspects of Rett syndrome pathogenesis via regulation of glutamate levels, homeostasis, and neuroinflammation (Kahanovitch et al., 2019; Maezawa et al., 2009) . As presented in Figure 3C , MECP2 silencing increased astrocytic differentiation of NSCs at the expense of neuronal differentiation. Treatment of the silenced NSCs with pacritinib or DMF did not have significant effects on markers of neuronal (bIII tubulin) or astrocytic (GFAP) differentiation ( Figure 5A ). In contrast, EPO abrogated the impaired NSC differentiation as reflected by an increase of bIII tubulin and a decrease of GFAP ( Figure 5A ). In human astrocytes, MECP2 silencing decreased the expression of the glutamate transporter EAAT2 ( Figure 3D ). Treatment of these cells with EPO and pacritinib 10 mM (C), and the expression of M1 and M2-associated markers were determined after 72 hr using RT-PCR. MECP2 silenced microglia cells treated with EPO, DMF, or pacritinib were also analyzed for phagocytosis using the pHrodo assay (D). MECP2-silenced microglia cells were transduced with lentivirus vectors expressing the NF-kB reporter followed by treatment with EPO, DMF, and pacritinib for 24 hr. Luciferase activity was determined (E). The results demonstrate the means ± SD of a representative experiment of three separate tests analyzed in quadruplet. *p<0.05, **p<0.01, ***p<0.001,****p<0.0001.

inhibited the decreased EAAT2 expression, whereas pacritinib and DMF did not have a significant effect ( Figure 5B ).

BDNF plays important roles in neuronal growth and development and represents a well-recognized transcriptional target of MECP2 (Chen et al., 2003) . Silencing of MECP2 decreased BDNF expression in both neurons and astrocytes ( Figure 6A-B) . DMF and EPO induced an increase in BDNF mRNA in the silenced neurons ( Figure 6A ) and in the silenced astrocytes ( Figure 6B) , whereas pacritinib did not exert a significant effect in either. We replicated this experiment in astrocytes, testing DMF and EPI both individually and in combination ( Figure 6C ). This showed a modest increase in the level of BDNF in the in the combined treatment, suggesting potentially independent modes of action.

Rett syndrome is a neurodevelopmental disease without evidence of degeneration and thus rescuing MECP2 downstream activity might improve disease pathophysiology even in adulthood (Faundez et al., 2019) . In murine models, reintroduction of MECP2 to adult animals led to vast phenotypic improvements (Guy et al., 2007) . In parallel with approaches aimed at increasing MECP2 levels directly (Brendel et al., 2011; Merritt et al., 2020; Przanowski et al., 2018) , accurate mapping of the MECP2 gene network is important to provide additional avenues for intervention, and avoid the toxicity associated with overexpression of MECP2 (Ramocki et al., 2009) . Here, we have presented a framework for identifying potential drug-gene interactions based on comparative genomics, and validate these interactions in human immortalized primary neural cells. We analyzed phylogenetic profiling across mammals and hundreds of eukaryotes to infer functional links and generated a network of co-evolved genes, identifying known targets such as IRAK1 as well as new candidates such as EPOR. We then mined this network to identify actionable drug targets, prioritizing a list of associated compounds using a combination of strong co-evolutionary evidence of the target proteins and a proven safety profile of approved pharmaceutical compounds (Pacritinib, DMF, and EPO). While we prioritized based on the potential for drug repurposing, our evolutionary analysis could also be used to identify additional targets for drug design. Furthermore, we only performed functional validation 3 of the 33 co-evolved genes associated with approved drugs, leaving others for potential future study. We reproduced a number of RTT phenotypes by reducing expression of MECP2 in human neural cell cultures. When treated with the three selected compounds, these phenotypes could all be reversed to different degrees in a cell-dependent manner. While all the compounds restored the polarization of microglia and reduced the hyperactivity of NF-kB signaling in microglia, only DMF abrogated decreased phagocytosis. EPO alone reversed the impaired neuronal/astrocyte differentiation of NSCs. In neurons and astrocytes, DMF and EPO abrogated the inhibitory effect of MECP2 silencing on BDNF expression and secretion, whereas pacritinib did not have a significant effect.

The activity of these compounds on microglia polarization and NF-kB activity is mechanistically interesting. Activation of microglia cells has been reported in MECP2 KO mice (Zhao et al., 2017) and has been associated with pathological process in RTT (Kahanovitch et al., 2019) . An MECP2 KO mouse model also implicated NF-kB signaling and IRAK1 as important mediators of the neuroinflammatory response in RTT (Kishi et al., 2016) . While the mechanisms involved in the reversing effects of these three compounds remains to be determined, NF-kB signaling downstream of MECP2 is an attractive candidate (Figure 7) . EPOR and KEAP1 have also been implicated as NF-kB modulators involved in the inflammatory response. The endogenous hormone EPO binds the TPR to suppresses inflammatory cytokines in immune cells, a process which involves inhibition of the NF-kB pathway through GSK3b (Patel et al., 2011) . NFE2L2, usually bound by KEAP1, also has a direct cytoplasmic role in modulating NF-kB signaling through degradation of IkB and nuclear translocation of NF-kB (Ganesh Yerra et al., 2013) . The three compounds tested all inhibited NF-kB-dependent luciferase activation in microglia cells to a certain extent, validating their involvement in this context.

In addition to the inflammatory effect, we found that MECP2 silencing decreased the neuronal while increasing the astrocytic differentiation of NSCs. However, human astrocyte function was impaired in the MECP2 silenced cells and these cells expressed lower levels of the glutamate transporter EAAT2. The signaling pathways involved in these effects of EPO are not fully characterized; however, NF-kB has been recently reported to regulate EAAT2 expression in astrocytes (Wei et al., 2019) .

Finally, we found that both DMF and EPO rescued the decreased BDNF expression in MECP2silenced microglia and astrocytes. Indeed, both NF-kB and NFE2L2 pathways have been reported to be associated with the regulation of BDNF expression (Caviedes et al., 2017; Nair and Wong-Riley, 2016) . Thus, DMF can increase BDNF levels through an increase in NFE2L2, which binds the BDNF promotor and acts as a transcriptional activator (Nair and Wong-Riley, 2016) . EPO administration activates the STAT3 signaling pathway (Rey et al., 2019) , which can in turn elevate BDNF expression (Chen et al., 2016) .

While the strong evolutionary linkage of our target proteins to MECP2 strongly suggest that they are mediating the reversal of MECP2 silencing phenotypes by their associated drugs, we have not ruled out the possibility for alternative action of these drugs or joint action upon our involving other protein targets. A good example of this are the HDAC chromatin modifiers, a group of genes which We propose that reduced MECP2 levels could lead to increase in ICAM1, ICAM3, IRAK1, and KEAP1 levels, and a decrease of EPOR levels within the tissue-protective receptor. (B) IRAK-1 plays a role in NF-kB activation through IKK activation, which leads to IkB phosphorylation and subsequent degradation, NF-kB nuclear translocation and the expression of its pro-inflammatory target genes. KEAP1 binds NFE2L2 and prevents its nuclear localization. NFE2L2 target genes inhibits NF-kB signaling through a non-transcriptional mechanism involving degradation of IkBa. EPO binds EPOR and enhances the activation of Akt, resulting in inhibition of GSK-3b and inhibition of NF-kB nuclear transport. did not come up as specifically linked to MECP2 in our evolutionary analysis but are well-known interactors. HDACs play a crucial role in neuronal development, and MECP2-mediated gene repression occurs mainly through HDAC recruitment via the Sin3a and NCoR complexes Ebert et al., 2013; Nan et al., 1998) . HDACs have been suggested as therapeutic targets for Rett Syndrome (Shukla and Tekwani, 2020) and HDAC6 inhibition has been linked to improved BDNF trafficking in a Rett mouse model (Xu et al., 2014) . Importantly, one of the compounds we examined, DMF, can reduce HDAC1/2/4 expression in rat astrocytes (Kalinin et al., 2013) , and EPO can promote phosphorylation of HDAC5 in rat hippocampal neurons (Jo et al., 2016) . It is thus plausible that HDAC inhibition mediates the effects we observe for these drugs, at least in part. However, the effects on HDAC activity are not the principal mechanisms of action of either of the proposed compounds (Kalinin et al., 2013; Jo et al., 2016) , nor do they have established interactions with the HDAC most implicated in RTT biology (HDAC6). Future studies should investigate if any of the MECP2-rescuing activities of these drugs act through HDACs in concert with or independent of the target proteins identified here.

In summary, EPO, DMF and pacritinib act differentially on MECP2-silenced NSCs, microglia and astrocytes, providing a preliminary validation of our approach. The investigation into specific drug effects and mechanisms of actions are important areas for future studies, as are drug combination assays and in-vivo studies of EPO, DMF and pacritinib using MECP2 KO mice. These will be to assess whether any of the identified drugs can be further be explored for clinical use.

Mapping MECP2 conservation along 1028 eukaryotic species and identifying correlated genes

We used the pipeline we described in Tsaban et al., 2021 to calculate the Normalized Phylogenetic Profile (NPP) of 1028 eukaryotic species and rank genes based on their evolutionary similarity to MECP2. Briefly, 20,192 human proteins (one representative protein sequence per gene) were downloaded from UniProt reference proteomes (June 2018 release) (Bateman and UniProt Consortium, 2019) . We used the Uniprot canonical isoform for each gene. For the 29 genes with more than one canonical isoform, we selected the longest isoform to maximize sequence information. The proteins were searched with BLASTP (Camacho et al., 2009 ) against the proteomes of the 1028 eukaryotes. A bit-score of 20.4, corresponding to a BLAST e-value of 0.05, was set as a minimal similarity threshold. The top scoring protein in each organism was selected. The bit-scores were normalized to protein length and phylogenetic distance from humans. The output is a matrix P of size 20,242 x 1028 where each entry Pab is the best BLASTP bit score between a human protein sequence 'a' and the top result in organism 'b'. The Pearson correlation was calculated for each profile with the MECP2 profile. The top 200 genes in all eukaryotes were selected as the E200 group for further analysis. This procedure was repeated using only the 51 mammal species, and the top 200 genes in were selected as the M200 group for further analysis.

Drug gene interactions were collected from DGIdb (Cotto et al., 2018) and from Open Targets (Oxford Academic, 2019). Drugs at any stage of development were included in the search as long as the interaction with the target gene had known directionality (e.g. inhibitory, activating). Druggene interactions were validated through a literature review and known gene-gene interactions were collected from STRING (Szklarczyk et al., 2019) . Network diagram was constructed using STRING and Cytoscape (Lopes et al., 2011) .

Gene locations were retrieved from BioMart (Kasprzyk, 2011) , the NCBI genome data viewer Figure 3A ). Synteny in ancestral species was obtained from Genomicus (Nguyen et al., 2018) . Intra-chromosomal Hi-C contact heatmaps and TAD borders were collected from the 3D Genome Browser (Wang et al., 2018) , using GM12878 cell data from the high-resolution Hi-C dataset of Rao et al., 2014. Neural cell cultures Immortalized human microglial cells and astrocytes were obtained from Applied Biological Material (Richmond, BC, Canada). Human NSCs (H9, hESC-derived) (ReNcell) were obtained from Invitrogen, Merck (Germany). Human neurons were obtained from ScienCell (Carlsbad, CA, USA). All cells employed in this study were tested for mycoplasma contamination (Mycoplasma PCR Detection Kit) and found negative.

Lentivirus vectors (System Biosciences, Mountain View, CA, USA) expressing the MECP2 or control shRNAs and the reporters GFP/fLuc GFAP, mCherry/Luc MAP2 and NF-kB luciferase were packaged and used to transduce the cells according to the manufacturer's protocol and as previously described (Giladi et al., 2015) .

Human NSCs were maintained as spheroids in an NSC maintenance medium containing fibroblast growth factor 2 (FGF-2) and an epidermal growth factor (EGF, 20 ng/ml) on laminin-coated flasks. For differentiation, the cells were maintained in NSC maintenance medium without FGF-2 and EGF and neuronal and glial differentiation were observed.

Human microglia cells were silenced for MECP2 using lentivirus vectors expressing MECP2 or control shRNAs. After 5e days, the expression of MECP2 was determined by western blot analysis and cells exhibiting a decrease of at least 80% were employed in further studies. Control and silenced cells were treated with the specific compounds and the expression of M1-and M2-associated markers were determined after 72 hr using RT-PCR. All experiments were done in triplicates and were repeated three times.

Cells were treated with different concentrations of DMF (1 10 and 50 mM), EPO (10, 30 and 50 ng/ ml), and Pacritinib (1 and 10 mM). Following 3 days of treatment, the cells were analyzed for cell death using LDH assay. The results are presented as the means ± SD of six samples for each compound.

Cell pellet preparation and Western blot analyses were performed as previously described (Lomonaco et al., 2009) . Equal loading was verified using an anti-b-actin or tubulin antibodies as described (Giladi et al., 2015; Bier et al., 2018) .

Total RNA was extracted using RNeasy midi kit according to the manufacturer's instructions (Qiagen, Frederick, MD, USA). Reverse transcription reaction was carried out using 2 mg total RNA (Bier et al., 2018) . The primer sequences are described in the supplementary files (Supplementary file 3).

Human microglial cells were silenced for MECP2. Phagocytosis was determined using the pHrodo Green zymosan bioparticle assay (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Briefly, microglia were incubated with a solution of pHrodo Green zymosan bioparticles in Live Cell Imaging Solution (0.5 mg/ml) for 2 hr. Phagocytosis was determined using a fluorescence plate reader at Ex/Em 509/533.

The firefly luciferase activity of the NF-kB, GFAP and MAP two activities and the control Renilla luciferase activity were analyzed using the Dual-Luciferase Reporter Assay System (Promega Corporation).

The results are presented as the mean values ± SD. Data were analyzed using a Student's t-test with correction for data sets with unequal variances (Welch's unequal variances t-test).

The phylogenetic data required to reproduce the analysis are openly available at Zenodo [https:// zenodo.org/record/4464120#.YEoFpHmxVPY]. Code used for the analysis is openly available through Github https://github.com/GuIrene/MECP2_phylogeny (copy archived at https://archive. softwareheritage.org/swh:1:rev:14063b44a40688a8024a06347b63cfdac74b96ad).

The following previously published dataset was used: 

Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2

Differentiation of multipotent neural stem cells derived from rett syndrome patients is biased toward the astrocytic lineage

MYORG is associated with recessive primary familial brain calcification

Decoding cilia function: defining specialized genes required for compartmentalized cilia biogenesis

UniProt: a worldwide hub of protein knowledge

GeneAnalytics: an integrative gene set analysis tool for next generation sequencing, RNAseq and microarray data

Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy

2020. miR-504 modulates the stemness and mesenchymal transition of glioma stem cells and their interaction with microglia via delivery by extracellular vesicles

Dimethyl fumarate: a review in moderate to severe plaque psoriasis

Optimization of co-evolution analysis through phylogenetic profiling reveals pathway-specific signals

ACE2 Coevolutionary pattern suggests targets for pharmaceutical intervention in the COVID-19 pandemic

Readthrough of nonsense mutations in rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model

Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor

BLAST+: architecture and applications

BDNF/NF-kB signaling in the neurobiology of depression

The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression

MeCP2: only 100% will doNat

Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2

Carbamylated erythropoietin: a prospective drug candidate for neuroprotection

Autocrine activity of BDNF induced by the STAT3 signaling pathway causes prolonged TrkB activation and promotes human non-small-cell lung Cancer proliferation

Pro-Inflammatory activation of A new immortalized human microglia cell line

DGIdb 3.0: a redesign and expansion of the drug-gene interaction database

Discovery of uncharacterized cellular systems by genome-wide analysis of functional linkages

Systematic discovery of human gene function and principles of modular organization through phylogenetic profiling

Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR

Phylogenetic analysis and gene functional predictions: phylogenomics in action

Phydbac2: improved inference of gene function using interactive phylogenomic profiling and chromosomal location analysis

Molecular systems biology of neurodevelopmental disorders, rett syndrome as an archetype

Chromosome territories and the global regulation of the genomeGenes Chromosom

Improved survival and reduced phenotypic severity following AAV9/ MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice

Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-kB pathways in diabetic neuropathy

Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of rett syndrome

RTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loop

Double-blind, randomized, placebo-controlled study of trofinetide in pediatric rett syndrome

Reversal of neurological defects in a mouse model of rett syndrome

Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma

The evolution of land plant cilia

MeCP2 as an activator of gene ExpressionTrends

Network based elucidation of drug response: from modulators to targets

The reactome pathway knowledgebase

The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model

Protein function predictions based on the phylogenetic profile method

MeCP2 deficiency in Neuroglia: new progress in the pathogenesis of rett syndrome

Erythropoietin and carbamylated erythropoietin promote histone deacetylase 5 phosphorylation and nuclear export in rat hippocampal neurons

Glial dysfunction in MeCP2 deficiency models: implications for rett syndrome

Dimethyl fumarate regulates histone deacetylase expression in astrocytes

KEGG: kyoto encyclopedia of genes and genomes

BioMart: driving a paradigm change in biological data management

ANAVEX2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of rett syndrome

Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of rett syndrome

Locally defined protein phylogenetic profiles reveal previously missed protein interactions and functional relationships, proteins struct

Reduction of aberrant NF-kB signalling ameliorates rett syndrome phenotypes in Mecp2-null mice

Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice

RettBASE: rett syndrome database update

Activity-dependent BDNF release and TRPC signaling is impaired in hippocampal neurons of Mecp2 mutant mice

Rett syndrome and MeCP2

The induction of autophagy by Iˆ3-radiation contributes to the radioresistance of glioma stem cells

Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor

Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions

Localizing proteins in the cell from their phylogenetic profiles

The Chlamydomonas genome reveals the evolution of key animal and plant functions

Pharmacological read-through of R294X Mecp2 in a novel mouse model of rett syndrome

Wide phenotypic spectrum of human stem cell-derived excitatory neurons with rett syndrome-associated MECP2 mutations

Dimethyl fumarate treatment in multiple sclerosis: recent advances in clinical and immunological studies

Transcriptional regulation of Brain-derived neurotrophic factor coding exon IX: role of nuclear respiratory factor 2

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

The support of human genetic evidence for approved drug indications

Specific mutations in methyl-CpG-binding protein 2 confer different severity in rett syndrome

Genomicus 2018: karyotype evolutionary trees and onthe-fly synteny computing

Methyl CpG binding protein 2 deficiency enhances expression of inflammatory cytokines by sustaining NF-kB signaling in myeloid derived cells

Alterations of gene expression and glutamate clearance in astrocytes derived from an MeCP2-null mouse model of rett syndrome

Open targets platform: new developments and updates two years on

A mitochondrial protein compendium elucidates complex I disease biology

Anaplerotic triheptanoin diet enhances mitochondrial substrate use to remodel the metabolome and improve lifespan, motor function, and sociability in MeCP2-Null mice

A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock

Assigning protein functions by comparative genome analysis: protein phylogenetic profiles

MeCP2: an epigenetic regulator of critical periods

Pharmacological reactivation of inactive X-linked Mecp2 in cerebral cortical neurons of living mice

Drug repurposing: progress, challenges and recommendations

MECP2, a multi-talented modulator of chromatin architecture | briefings in functional genomics | oxford academic, br

Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome

A 3D map of the human genome at Kilobase resolution reveals principles of chromatin looping

Erythropoietin as a neuroprotective molecule: an overview of its therapeutic potential in neurodegenerative diseases

CORUM: the comprehensive resource of mammalian protein complexes

High-resolution mapping reveals a conserved, widespread, dynamic mRNA methylation program in yeast meiosis

Mapping global and local coevolution across 600 species to identify novel homologous recombination repair genes

Transcriptome level analysis in rett syndrome using human samples from different tissuesOrphanet

Histone deacetylases inhibitors in neurodegenerative diseases, neuroprotection and neuronal differentiation

Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy

Refined phylogenetic profiles method for predicting proteinprotein interactions

STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

Human disease locus discovery and mapping to molecular pathways through phylogenetic profiling

Identification of small RNA pathway genes using patterns of phylogenetic conservation and divergence

An overview of in vitro methods to study microglia

Disease-modifying treatments for multiple sclerosis -a review of approved medications

CladeOScope: functional interactions through the prism of clade-wise co-evolution

IL-38 inhibits microglial inflammatory mediators and is decreased in amygdala of children with autism spectrum disorder

MECP2_phylogeny. Software Heritage. swh:1:rev: 14063b44a40688a8024a06347b63cfdac74b96ad

Treating rett syndrome: from mouse models to human therapies

The 3D genome browser: a web-based browser for visualizing 3D genome organization and longrange chromatin interactions

Wnt1 promotes EAAT2 expression and mediates the protective effects of astrocytes on dopaminergic cells in Parkinson's Disease

A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for rett syndrome

Species and cell-type properties of classically defined human and rodent neurons and Glia

Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes

Glioblastoma-Derived extracellular vesicles facilitate transformation of astrocytes via reprogramming oncogenic metabolism

Transcriptome analysis of microglia in a mouse model of rett syndrome: differential expression of genes associated with microglia/macrophage activation and cellular stress

We thank Dr. Yaron Daniely and the Yissum team for being a major driving force for this project. We thank Dr. Liana Patt and the Integra Holdings team for their support. We thank Dr. Hae Kyung Lee and Susan Finniss for their technical support. Figures include vector images designed by Freepik. We thank Dr. Amir Eden and Prof. Yinon Ben Neriah for their insight and comments. Funding: This project was supported by an Israel Science Foundation grant 1591/19 to YT and by Integra Holdings. Additional support to BPB and IU came from a grant from the Beethoven Foundation.

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.